Growth outlook for the anticancer drug and genomic research markets
First written in FY2016. 14 of 15 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2025RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2023-Q3RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2023-Q1RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2022-Q3RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2022-Q1RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2021-Q3RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2021-Q2RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2021-Q1RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2020-Q3RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2020-Q2RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2020-Q1RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including the aging population, the increase in early detection through cancer diagnosis, the emergence of molecularly targeted therapies, and advances in cancer precision medicine. The Group expects the market to continue expanding in the future.」
The company continues to forecast that the anticancer drug market will expand due to the aging population, early detection, molecularly targeted therapies, and advances in cancer precision medicine. - FY2018RestatedAnnual report
「The market surrounding the anticancer drug sector, which is closely related to the Group's business, is expanding due to factors including ① the aging population, ② the increase in early detection through cancer diagnosis, ③ the emergence of molecularly targeted therapies, and ④ advances in personalized cancer medicine. The Group expects the market to continue expanding in the future.」
The company continues to cite the growth outlook for the anticancer drug market, including advances in personalized cancer medicine as a contributing factor. - FY2017RestatedAnnual report
「The market is expanding due to the aging population, the increase in early detection through cancer diagnosis, which is leading to an increase in long-term treatment, and the emergence of molecularly targeted therapies, among other factors. The Group expects the market to continue expanding in the future.」
The company continues to cite the growth outlook for the anticancer drug market as a business opportunity and as a factor behind increased market entry and competition. - FY2016First statedAnnual report
「The market is expanding due to the aging population, the increase in early detection through cancer diagnosis, which is leading to an increase in long-term treatment, and the emergence of molecularly targeted therapies, among other factors. The Group expects the market to continue expanding in the future.」
The company explains that market expansion represents a business opportunity while also contributing to an increase in market entrants and competitors.